UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C.  20549 

  
 

FORM 8-K 
CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934 
Date of report (Date of earliest event reported):  December 21, 2007
GENTA INCORPORATED 
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)

  
     
     
     

  
    0-19635

(Commission File Number) 
     
    33-0326866

(IRS Employer Identification No.)

  
     
     
     

  
    200 Connell Drive

Berkeley Heights, NJ

(Address of Principal Executive Offices) 
     
    

07922

(Zip Code)


(908) 286-9800

(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)

  
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions: 

  
    o
     
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
     

  
    o
     
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
     

  
    o
     
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  
     

  
    o
     
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 
 






Item 8.01 Other Events. 
On December 21, 2007, Genta Incorporated, (the Company), announced that the Company has received notice from the Food and Drug Administration (FDA) that FDA has extended its review period of Genta’s request for correction of certain information that was filed pursuant to the Information Quality Act for an additional 60 days. The requested correction relates to FDA’s assessment of progression-free survival (PFS) in the Phase 3 trial of Genasense® (oblimersen sodium injection) that was presented to the Oncology Drug Advisory Committee (ODAC) that considered Genta’s New Drug Application for Genasense in patients with advanced melanoma.
Item 9.01 Financial Statements and Exhibits.

  
    
      
(d) Exhibits.



 

  
    
      
Exhibit

          Number
      
 
      
Description

    
      
99.1
      
 
      
Press Release of the Company dated December 21, 2007



 
 






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

  
    
      
 
      
 
      
GENTA INCORPORATED 



    
      


Date: December 21, 2007
      
 
      


By:
      


/s/ RICHARD J. MORAN

    
      
 
      
 
      
 
      
 
      
Name: 
      
Richard J. Moran

    
      
 
      
 
      
 
      
 
      
Title:
      
Senior Vice President, Chief Financial 

          Officer and Corporate Secretary



 
 






EXHIBIT INDEX
 

  
    
      
Exhibit 

          Number
      
 
      
Description
      
 
      
Sequentially 

          Numbered Page

    
      
99.1
      
 
      
Press Release of the Company dated December 21, 2007